Lipid-Based Pharmaceutical Nanocarriers for Imaging Applications - Nanotechnology for Biomedical Imaging and Diagnostics - page 73

[49] phillips WT, rudolph As, goins B, Timmons JH, Klipper r, Blumhardt r. A simple
method for producing a technetium-99m-labeled liposome which is stable in vivo . int J
rad Appl instrum B 1992; 19 :539-547.
[50] suresh m, Cao Y. A simple and efficient method for radiolabeling of preformed lipo-
somes. J pharm pharm sci 1998; 1 :31-37.
[51] Bao A, goins B, Klipper r, Negrete g, mahindaratne m, phillips WT. A novel liposome
radiolabeling method using 99mTc-“sNs/s” complexes: in vitro and in vivo evaluation.
J pharm sci 2003; 92 :1893-1904.
[52] Barenholz Y, Amselem s, goren d, Cohen r, gelvan d, samuni A, golden EB, gabizon
A. stability of liposomal doxorubicin formulations: problems and prospects. med res
rev 1993; 13 :449-491.
[53] ogihara-umeda i, sasaki T, Nishigori H. development of a liposome-encapsulated
radionuclide with preferential tumor accumulation—the choice of radionuclide and che-
lating ligand. int J rad Appl instrum B 1992; 19 :753-757.
[54] seltzer sE. The role of liposomes in diagnostic imaging. radiology 1989; 171 :19-21.
[55] sachse A, Leike Ju, rossling gL, Wagner sE, Krause W. preparation and evaluation of
lyophilized iopromide-carrying liposomes for liver tumor detection. invest radiol
1993; 28 :838-844.
[56] Leike Ju, sachse A, rupp K. Characterization of continuously extruded iopromide-
carrying liposomes for computed tomography blood-pool imaging. invest radiol 2001;
36 :303-308.
[57] Krause W, Leike J, sachse A, schuhmann-giampieri g. Characterization of iopromide
liposomes. invest radiol 1993; 28 :1028-1032.
[58] Elbayoumi TA, Torchilin Vp. use of radiolabeled liposomes for tumor imaging. in: Bulte
JWm, modo m, editors. Nanoparticles in Biomedical Imaging . 1st ed. New York:
springer; 2007. p 211-236.
[59] senior JH. fate and behavior of liposomes in vivo : a review of controlling factors. Crit
rev Ther drug Carrier syst 1987; 3 :123-193.
[60] Torchilin Vp. drug targeting. Eur J pharm sci 2000; 11 (suppl 2):s81-s91.
[61] Torchilin V. Antibody-modified liposomes for cancer chemotherapy. Expert opin drug
deliv 2008; 5 :1003-1025.
[62] Torchilin Vp. recent advances with liposomes as pharmaceutical carriers. Nat rev drug
discov 2005; 4 :145-160.
[63] Weissig VV, Babich J, Torchilin VV. Long-circulating gadolinium-loaded liposomes:
potential use for magnetic resonance imaging of the blood pool. Colloid surf B
2000; 18 :293-299.
[64] papisov mi. modeling in vivo transfer of long-circulating polymers (two classes of long-
circulating polymers and factors affecting their transfer in vivo ). Adv drug deliv rev
1995; 16 :127-139.
[65] Torchilin Vp, omelyanenko Vg, papisov mi, Bogdanov AA Jr, Trubetskoy Vs, Herron
JN, gentry CA. poly(ethylene glycol) on the liposome surface: on the mechanism of
polymer-coated liposome longevity. Biochim Biophys Acta 1994; 1195 :11-20.
[66] Allen Tm. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake
of liposomes by the mononuclear phagocyte system. Adv drug deliv rev 1994; 13 :
285-309.
[67] Allen Tm. Long-circulating (sterically stabilized) liposomes for targeted drug delivery.
Trends pharmacol sci 1994; 15 :215-220.